This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

As Keryx, Aeterna Shares Surge, Investing Writer's Credibility Questioned

Stocks in this article: KERX AEZS

One of the disputes centers on claims made by Richards that he and his associates own large stock holdings in Keryx and Aeterna. Richards often cites those holdings in his Seeking Alpha articles as proof that perifosine is an effective cancer therapy.

Private Wealth Fund isn't a shareholder of Aeterna or Keryx, according to Bloomberg data that compiles such information on publicly traded companies. In fact, Private Wealth Fund doesn't show up at all as a stock fund, according to Bloomberg. It's not known if Richards owns stock in the companies through a personal account.

Aeterna has no information on Private Wealth Fund as an investor in the company and its executives don't know Richards, according to Aeterna spokesman Paul Burroughs.

Keryx didn't respond to questions about Richards or Private Wealth Fund.

In the March 2 article, Richards says his biotech consultant, "Dr. Williams" -- no first name or affiliation are disclosed -- owns 1.2 million shares of Aeterna.

"We value his opinion immensely and his track record is impeccable," Richards writes of Williams.

Williams doesn't show up as an Aeterna investor, according to Bloomberg. Any holder of 1.2 million shares of Aeterna today would be its second-largest shareholder, right behind RCM Capital Management's 1.4 million Aeterna shares, Bloomberg data show.

Richards, in his March 2 article, claims that another of his consultants, "well-respected" surgical oncologist Dr. Fred Wurlitzer, owns about 1 million shares of Aeterna because "he firmly believes in the success of perifosine."

Wurlitzer doesn't show up as an Aeterna shareholder, per Bloomberg.

"Whether Williams or Wurlitzer own Aeterna shares or not is not for us to comment on. We wouldn't know them unless they were 5% holders and they aren't," Aeterna's Burroughs says.

As further support for his articles touting the cancer drug perifosine, Richards claims that Williams owns 800,000 shares of Keryx. If true, the stake would make him the 13th-biggest investor in the company.

When asked for confirmation by Seeking Alpha, Richards said neither Williams nor Wurlitzer own more than 5% of Aeterna or Keryx, which explains why they're not listed as shareholders lists compiled by Bloomberg or Thomson Reuters, Moriarty said.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs